Annual report 2024
High-precision delivery
medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. medmix shares are listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105).
Read more about medmix here
Letter to the shareholders
)
Our KEY Figures
483.9m CHF
revenue in 2024
19.1%
adjusted EBITDA margin
39.6m CHF
free cash flow generated in 2024
The medmix strategy: platform for growth
The medmix approach to sustainability
